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Summary Serious infections caused by Gram-positive bacteria are currently dif-
ﬁcult to treat because many of these pathogens are now resistant to standard
antimicrobial agents. As a result of the emergence and spread of multidrug-resistant
Gram-positive pathogens, new antimicrobial agents are urgently needed for clinical
use. In recent years, there has been an increase in the number of drugs that have
activity against these Gram-positive pathogens. Daptomycin, tigecycline, linezolid,
quinupristin/dalfopristin and dalbavancin are ﬁve antimicrobial agents that are use-
ful for the treatment of infections due to drug-resistant Gram-positive cocci. This
review focuses on their mechanism of action, pharmacokinetics, spectrum of activ-
ity, clinical effectiveness, drug interaction and safety. These antimicrobial agents
provide the clinician with additional treatment options among the limited therapies
for resistant Gram-positive bacterial infection.
© 2009 Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University
for Health Sciences. All rights reserved.
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ntroduction
erious infections caused by Gram-positive bacteria
ontinue to pose signiﬁcant treatment chal-
enges. These difﬁcult-to-treat pathogens which
nclude methicillin-resistant Staphylococcus aureus
MRSA), vancomycin-resistant enterococci (VRE),
ancomycin intermediate and resistant S. aureus
VISA and VRSA), coagulase-negative staphylococci
CoNS) and penicillin-resistant Streptococcus pneu-
oniae (PRSP) have assumed world-wide notoriety
ith associated increasing morbidity and mortality
1,2]. Hence, there is an urgent need for effec-
ive novel antibiotics which not only target these
athogens but also possess suitable pharmacoki-
etic properties and safety proﬁles. In recent years,
e have witnessed signiﬁcant advances in drug
evelopment which have resulted in the introduc-
ion of new antibiotics into the armamentarium
vailable to clinicians. This review presents an anal-
sis of ﬁve new generation antibiotics (daptomycin,
igecycline, linezolid, quinupristin/dalfopristin and
albavancin) some of which are currently in use
n clinical settings. The dosages, route of admin-
stration and side-effects of the drugs are shown in
able 1.
aptomycin
his new semi-synthetic cyclic lipopeptide was
pproved by the Food and Drug Administration
FDA) in 2003 for the treatment of complicated
kin and soft tissue infections (cSSI) caused by
usceptible Gram-positive pathogens and European
pproval was granted in January 2006 [3]. Its chem-
cal structure is composed of a 13-amino acid cyclic
eptide with a hydrophilic core and a lipophilic tail
4]. The short peptide chains conjugated with an
a
r
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cyl chain form a structurally deﬁned conformation
hich is responsible for the unique mechanism of
ction of daptomycin. The insertion of the lipophilic
ail into the bacterial membrane results in the for-
ation of pores with leakage of cellular material,
issipation of the transmembrane potential as well
s widespread disruption of macromolecular syn-
hesis ultimately culminating in a rapid bactericidal
ffect [5].
In vitro and in vivo studies have demonstrated
hat daptomycin is effective in a concentration-
ependent manner, has a long half-life (8 h) and
emonstrates a prolonged post-antibiotic effect of
p to 6.8 h, hence the recommendation is for a
nce daily dosing [6,7]. Due to its poor absorption
ia the gastrointestinal tract, parenteral admin-
stration is necessary to achieve adequate serum
oncentration. Daptomycin is highly bound to serum
roteins and is primarily distributed in the extra-
ellular ﬂuid with penetration to vascular tissues
3,8,9]. However, it fails to cross the blood—brain
arrier or penetrate the cerebrospinal ﬂuid of nor-
al individuals. Additionally, animal studies have
emonstrated poor penetration of daptomycin into
he alveolar lining [10]. Drug elimination occurs
hrough the renal mechanism and it is excreted
argely unchanged in the urine. The normal 8 h half-
ife of daptomycin increases to as high as 30 h when
here is renal impairment, hence dose adjustment
s mandatory for patients with renal failure [11]. As
aptomycin does not induce or inhibit the activi-
ies of cytochrome P450 or other hepatic enzymes
nd because of its unique mechanism of action, no
ntagonistic drug interactions have been observed
12].Daptomycin’s antimicrobial effect is directed
gainst Gram-positive bacteria including multidrug-
esistant strains [13,14]. Its spectrum of activ-
ty encompasses methicillin-sensitive Staphylo-
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Table 1 Characteristics of newer antimicrobial agents used in the therapy of infections caused by drug-resistant Gram- positive cocci.
Drug Route Dosage Indications Adverse effects
Daptomycin IV 4mg/kg/day for
cSSI; 6mg/kg/day
for bacteremia
1. Complicated skin and skin
structure infections (cSSSI) caused
by methicillin-sensitive
Staphylococcus aureus (MSSA),
methicillin-resistant S. aureus
(MRSA), Streptococcus. pyogenes,
S. agalactiae, S. dysgalactiae and
Enterococcus faecalisa. 2.
Bacteremia/right-sided infective
endocarditic caused by MSSA and
MRSAa
Clinical: constipation, nausea and
headache; laboratory: increased
creatinine phosphokinase [8,9]
Tigecycline IV Loading dose of
100mg, followed by
a maintenance dose
of 50mg every 12 h
1. Complicated intra-abdominal
infections including MRSA in
adultsa. 2. cSSSI including MRSA in
adultsa
Clinical: nausea, vomiting,
diarrhoea, headache, hypertension
and fever [35,36]
Linezolid Oral or IV 600mg orally/IV
every 12 h
1. Nosocomial and
community-acquired pneumoniaa.
2. Uncomplicated and complicated
skin infectionsa. 3.
Vancomycin-resistant Enterococcus
faecium (VREF) including cases
with bacteremiaa
Clinical: diarrhoea, headache,
nausea and vomiting; laboratory:
thrombocytopenia [56]
Quinupristin/dalfopristin IV 7.5mg/kg every 8 h 1. Serious infections associated
with VREFa. 2. cSSI caused by MSSA
and S. pyogenesa
Clinical: arthralgia, myalgia,
nausea, vomiting, rash, pain and
pruritus; laboratory:
hyperbilirubinemia and elevated
liver enzymes [68]
Dalbavancin IV 1000mg on day 1
and 500mg on day 8
1. Skin and soft-tissue infections.
2. Catheter-related bloodstream
infections caused by Gram-positive
pathogens (including MRSA)
Clinical: oral candidiasis,
diarrhoea, constipation and febrile
response [74,75]
a Approved by The U.S. Food and Drug Administration (FDA).
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occus aureus (MSSA), methicillin-resistant S.
ureus (MRSA), vancomycin-intermediate resistant
. aureus (VISA), vancomycin-resistant Enterococ-
us faecalis and E. faecium (VRE), coagulase-
egative staphylococci (CNS), streptococci (S.
neumoniae, S. pyogenes, S. agalactiae, S. dys-
alactiae subsp. Equimilis) and penicillin-resistant
. pneumoniae (PRSP) [7]. It is also of interest that
n vitro activity has been demonstrated against the
ecently isolated Michigan and Pennsylvania (Her-
hey) strains of vancomycin-resistant S. aureus with
inimum inhibitory concentrations (MICs) of 1.0
nd 0.5mg/L, respectively [9]. Additionally, dapto-
ycin has been shown to have potent antimicrobial
ctivity against Corynebacterium spp. and a variety
f anaerobic species [15,16].
linical trials
he vast majority of daptomycin clinical trials
ave been in patients with complicated skin and
kin structure infections (cSSSI), S. aureus bac-
eremia and right-sided endocarditis, urinary tract
nfections (UTI) and pneumonia. In 2004, Arbeit
t al. [17], reported the ﬁndings of two interna-
ional Phase 3 multicenter, randomized, controlled,
valuator-blinded trials comparing the safety and
fﬁcacy of daptomycin with that of conventional
herapy for the treatment of patients with cSSSI
equiring hospitalization. In both trials patients
ere randomized to receive either daptomycin
dministered at 4mg/kg intravenously (iv) qd by
0min infusion or comparator regimen comprising
f either cloxacillin, nafcillin, oxacillin or ﬂu-
loxacillin (4—12 g iv qd in equally divided doses),
r vancomycin, 1 g iv q12 h by 60min infusion. The
ndings of both trials clearly demonstrated that
he efﬁcacy of daptomycin therapy was not infe-
ior to that of comparator therapy [17]. Across
oth studies ∼83% of the patients were clinically
valuable and the success rate in this population
as 83.4% and 84.2% (95% conﬁdence interval [CI],
4.0 to 5.6) for daptomycin- and comparator-agent
reated patients, respectively. Indeed, similar ﬁnd-
ngs were still demonstrable with analysis of the
ombined intention to treat population with suc-
ess rates of 71.5% and 71.1% (95% CI, −5.8 to
.0) for daptomycin- and comparator-agent treated
rms, respectively. Among patients successfully
reated with iv daptomycin, a signiﬁcantly shorter
uration of therapy was observed with 63% requir-
ng 47 days of therapy, compared with 33% of
omparator-treated patients (p < 0.0001). Addition-
lly, on evaluation 3—4 weeks post-treatment, the
aptomycin treated patients tended to have a low
ncidence of relapsing or recurrent infection. The
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verall clinical success rates observed in these tri-
ls are comparable with those reported for other
ntimicrobial agents approved for the treatment of
SSSIs including quinupristin—dalfopristin thus vali-
ating daptomycin’s usefulness in the treatment of
SSSIs.
The efﬁcacy of daptomycin versus standard ther-
py in staphylococcal bacteremia was evaluated in
recently reported international, multicenter, ran-
omized, controlled open-label phase 3 study [18].
atients with S. aureus bacteremia with or without
ndocarditis were randomized to receive either iv
aptomycin 6mg/kg body weight or standard regi-
en of initial low-dose gentamicin plus either an
ntistaphylococcal penicillin or vancomycin. The
rimary efﬁcacy end point was treatment success
2 days after the end of therapy. The reported
ndings indicate that daptomycin is not inferior
o standard therapy for S. aureus bacteremia and
ight-sided endocarditis. The clinical success rate
or daptomycin treated patients was 44.2% (53/120)
ompared to 41.7% (48/115) for patients who
eceived standard therapy. The pathogen eradica-
ion rate was higher for daptomycin compared to
tandard therapy (19 versus 11 patients, p = 0.17).
n addition, adverse events resulting in the dis-
ontinuation of therapy were signiﬁcantly higher
mong patients receiving the standard therapy (17
ersus 8, p = 0.06). As the efﬁcacy of daptomycin
s comparative to standard antibiotic regimen with
he added advantage of fewer adverse events,
his antibiotic therefore represents a new treat-
ent option for S. aureus bloodstream infections.
long a similar trend, daptomycin and ciproﬂoxacin
ave been shown to have similar efﬁcacy against
ram-positive organisms (mostly E. faecalis and S.
ureus) for the treatment of complicated UTI [19].
A contrasting ﬁnding has been reported for the
se of daptomycin in the treatment of pneumonia.
n Phase 2 clinical trials, daptomycin (4mg/kg every
4 h) was compared against ceftriaxone (2 g every
4 h) for the treatment of hospitalized patients
ith community-acquired pneumonia. The ﬁndings
ndicate that daptomycin which showed clinical
fﬁcacy in 79% of subjects was signiﬁcantly inferior
o ceftriaxone (87% efﬁcacy). Subsequent stud-
es using animal models indicate that daptomycin
ppears to interact in vitro with pulmonary surfac-
ant, resulting in inhibition of antibacterial activity
20].afety proﬁle
he safety proﬁle of any new antibiotic is rel-
vant to its use in clinical practice. In several
linical studies of daptomycin therapy in adults,
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the most common adverse effects reported include
diarrhoea, rash, dizziness, dyspnoea and hypoten-
sion [3,5,17]. Other adverse events include skeletal
muscle symptoms and elevated levels of crea-
tine phosphokinase (CPK). Although the latter has
been reported in just about 3% of drug-treated
patients, it is still recommended that CPK levels
be checked weekly in adults receiving daptomycin
therapy. Daptomycin-associated myopathy is mild,
reversible and dose dependent and can easily be
recognized and conﬁrmed by measuring the CPK
levels [21].
Tigecycline
Tigecycline is the ﬁrst member of a new class of
antibiotics called glycylcyclines [22]. The glycylcy-
clines are derivatives of the tetracycline antibiotics
with structural modiﬁcations which confer potent
activity against Gram-positive, Gram-negative and
anaerobic bacteria including multidrug-resistant
strains [23]. Tigecycline is a structural analogue of
minocyline designed to overcome the major bacte-
rial resistance mechanisms such as efﬂux pumps,
target site modiﬁcations, DNA gyrase mutations
and beta-lactamase production. It consists of a
central four-ring carbocyclic skeleton with a substi-
tution at the D-9 position which confers expanded
broad-spectrum activity and decreased suscepti-
bility antibiotic resistance mechanisms [24,25]. By
binding reversibly to the 30S ribosomal subunit,
tigecycline interrupts the process of protein trans-
lation via inhibition of entry of amino-acyl transfer
RNA (t-RNA) molecules thus producing a bacterio-
static effect [26]. Additionally, tigecycline uniquely
binds to other sites of the ribosome, interfering
with the mechanism of production of ribosomal
proteins. Indeed, the ribosomal binding afﬁnity of
tigecycline has been shown to be up to ﬁve times
greater than that of the tetracyclines [27,28]
Similar to daptomycin, tigecycline is poorly
absorbed following oral administration hence this
antibiotic is only available as an intravenous prepa-
ration. It is administered by slow iv infusion, 100mg
stat, followed by 50mg 12 hourly. Over two thirds of
the drug is bound to serum proteins and with a high
volume of distribution of about 7—10 L/kg, tige-
cycline is extensively distributed into the tissues
[26,29]. It has been shown that following a single
100mg dose of iv tigecycline considerably higher
tissue/ﬂuid drug concentrations is demonstrable
in the bile, gallbladder, colon and lung compared
with simultaneous serum concentrations [29]. Tige-
cycline is not extensively metabolized, thus it is
largely eliminated unchanged via the biliary (60%)
b
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nd renal (22%) mechanisms [26]. Although it has
long half-life of 36 h, in moderate to severe hep-
tic impairment systemic clearance of the drug is
educed by 25—53% resulting in a 23—43% increment
n the elimination of half-life. Thus, reduced dos-
ng regimen of 25mg 12 hourly is recommended for
atients with signiﬁcant hepatic impairment [26].
Tigecycline is a broad-spectrum antibiotic with
otent activity against many Gram-positive and
ram-negative bacteria including many multidrug-
esistant strains such as MRSA, MRSE, PRSP and
RE species as well as ESBL-producing Escherichia
oli and Klebsiella spp. [30,31]. Additionally, it has
een shown to be effective against Acinetobacter
aumannii, Enterobacter spp., Serratia marcescens
nd Stenotrophomonas maltophilia isolates [32].
owever, it does not exhibit activity against Pseu-
omonas aeruginosa and Proteus spp. Due to its
otent microbiological and excellent therapeutic
esponse as reported in phase 3 human clinical tri-
ls, tigecycline has received FDA approval for the
reatment of infections of skin and skin structures,
s well as intra-abdominal infections. Emerging
ata also indicate its potential use for the empirical
reatment of nosocomial and community-acquired
nfections, including those caused by resistant
athogens [32,33].
linical trials
he clinical effectiveness of tigecycline has been
tudied in patients with cSSSI, complicated intra-
bdominal infections (cIAI), UTIs as well as
ommunity- and hospital -acquired pneumonia. In
wo large phase 3 studies, 1116 cSSSI patients were
andomized to receive either tigecycline (100mg
tat, followed by 50mg iv 12 hourly) or comparator
egimen of iv vancomycin 1 g twice daily (bid) plus
v aztreonam 2 g bid for up to 14 days [34]. Clini-
al success rates (intention to treat analysis) in the
igecycline arm were 79.7% (95% CI, 76.1—83.1%)
ersus 81.9% (95% CI, 78.3—85.1%) (p = 0.42) for
ancomycin—aztreonam therapy. In addition, rates
f occurrence of adverse events were similar in
oth treatment groups. The conclusion from this
ooled analysis was that tigecycline monotherapy
s of comparative efﬁcacy and safety proﬁle to
ancomycin—aztreonam combination in the man-
gement of cSSSI [34].
In 2005, Babinchak et al. [35] reported the
ooled analysis of two large prospective, double-
lind, phase 3 trials, which evaluated the efﬁ-
acy and safety of tigecycline compared with
mipenem—cilastatin in the treatment of patients
ith cIAI. In both trials patients were ran-
omly assigned to receive either iv tigecycline
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100mg, followed by 50mg given bid) or iv
mipenem/clistatin 500/500mg given every 6 h for
4 days [36]. The ﬁndings indicated clinical cure
ates of 80.2% for tigecycline in the microbiological
odiﬁed intent-to-treat population, versus 81.5%
or imipenem—cilastatin with similar trends in
dverse events in both treatment arms. These ﬁnd-
ngs conﬁrmed the efﬁcacy and safety of tigecycline
n the treatment of cIAI [35]. In a recent report,
nalysis of data from these trials using multiple
egression models also demonstrated that tigecy-
line was similar to imipenem—cilastatin in terms of
ealth resource utilization including duration of iv
ntibiotic therapy and length of hospital stay [37].
igecycline has been shown to be effective against
solates obtained from patients with community-
nd hospital-acquired pneumonias [32]. Recent
ata from a double-blind randomized phase 3
omparison study of intravenous tigecycline and
evoﬂoxacin in treatment of community-acquired
neumonia demonstrated comparable cure rates
or both drugs [38]. However, occurrence of nausea
nd vomiting was signiﬁcantly higher in the tigecy-
line treated patients.
afety proﬁle
igecycline is not an inducer of the CY P450 sys-
em and it has been shown to be relatively safe
ith the most frequently reported adverse events
eing nausea, vomiting and diarrhoea [22]. The
rug interactions of tigecycline are similar to those
f tetracyclines. The concurrent use of tigecycline
ith oral contraceptives may reduce contraceptive
fﬁcacy. For patients taking warfarin, prothrombin
imes or other anticoagulation parameter should
e monitored as tigecycline is capable of decreas-
ng the clearance of warfarin by 23—40% and can
lso increase the peak plasma concentration of war-
arin.
inezolid
his oxazolidinone drug was originally developed as
monoamine oxidase inhibitor for the treatment
f depression and its antimicrobial property was a
hance discovery [39]. Linezolid inhibits bacterial
ibosomal protein synthesis. However, the mecha-
ism by which it achieves this is unique as it targets
he ﬁrst step in protein synthesis by binding to the
0S ribosomal subunit close to its interface with the
0S unit causing distortion of the tRNA binding site.
his prevents formation of a 70S initiation com-
lex, which includes fMet transfer RNA, messenger
NA and the two ribosomal subunits [39—41]. As
T
o
m
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his mechanism of action is different from that
een in other inhibitors of protein synthesis such
s aminoglycosides, macrolides and tetracyclines,
ccurrence of cross-resistance is avoided.
Linezolid is rapidly and completely absorbed
fter oral administration with peak plasma con-
entrations reached within 1—2h with 100%
ioavailability. Approximately one third of the drug
s bound to serum proteins and the volume of dis-
ribution at the steady state is 40—50 L with a
alf-life of 4.5—5.5 h after a single oral or iv dose
42]. It is extensively distributed into skin, soft
issue, lung, heart, intestine, liver, urine, kidney
nd cerebrospinal ﬂuid (CSF). Additionally, fairly
ood tissue penetration as well as adequate pen-
tration into the synovial ﬂuid, bone, gallbladder
nd bile is achieved. It is metabolized primarily by
low non-enzymatic oxidation to inactive carboxylic
cid derivatives and it does not induce or inhibit
he activities of the CY P450. Elimination occurs
argely via non-renal mechanism (65%) with renal
nd fecal mechanisms accounting for 30% and 5%,
espectively [39,42]. Available data indicates that
osage adjustment in mild/moderate renal impair-
ent is not required, although it might be necessary
n patients with severe renal insufﬁciency or end-
tage renal disease undergoing haemodialysis [43].
Linezolid has bacteriostatic activity against
any important pathogens including most Gram-
ositive species [44—46]. It is active against MSSA
nd MRSA, as well as glycopeptide-susceptible
r resistant enterococci (both Van A and Van
phenotypes), PRSP and erythromycin-resistant
neumococci, Viridans streptococci, erythromycin-
esistant S. pyogenes and S. agalactiae. It is
lso active against anaerobes including Clostrid-
um perfringens, C. difﬁcile, Peptostreptococcus
pp., Bacteroides fragilis, Fusobacterium nuclea-
um and F. meningosepticum [47]. Although there
re no clinical trials on the efﬁcacy of linezolid
herapy for central nervous system infections, phar-
acokinetics and clinical data in neurosurgical
atients indicate the potential efﬁcacy of the
rug in the treatment of nosocomial Gram-positive
NS infections including those caused by Nocar-
ia spp. [48,49]. Anecdotal case reports indicate
favourable outcome with the use of linezolid in
eningitis caused by Gram-positive bacteria includ-
ng MSSA, MRSA and PRSP.
linical trialso date, the clinical effectiveness of linezolid has
nly been studied in patients with cSSSI, nosoco-
ial pneumonia, community-acquired pneumonia
nd infections due to MRSA and VRE [50]. In skin
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and soft tissue infections, the efﬁcacy of linezolid
has been evaluated in several multinational tri-
als. In a large phase 3 clinical trial, 826 patients
with cSSSI were randomized to receive either line-
zolid 600mg iv 12 hourly or iv oxacillin 2 g 6 hourly
[51]. Clinical success rates were observed in 88.6%
and 85.8% for linezolid and oxacillin, respectively.
Similar trend for microbiological success rates was
observed (linezolid 88.1% versus Oxacillin 86.1%). In
another multicenter multinational trial comparing
linezolid versus vancomycin for the treatment of
cSSSIs, the intention-to-treat analysis of the study
population showed that 92.2% and 88.5% of patients
treated with linezolid and vancomycin, respectively
were clinically cured at the test-of-cure visit [52].
Furthermore, sub-analysis of those with cSSSI due
to MRSA showed signiﬁcantly shorter hospital stay,
decreased treatment duration and higher discharge
rates for the linezolid arm [53]. These ﬁndings indi-
cate that the efﬁcacy of linezolid is equivalent to
that of vancomycin for the treatment of cSSSI and
where MRSA is the aetiological agent, linezolid is
superior to vancomycin. In other reported work,
where the efﬁcacy of linezolid for MRSA infec-
tions was evaluated in a randomized open-label
trial comparing linezolid (600mg, 12 hourly) with iv
vancomycin (1 g, 12 hourly) [54], no statistically sig-
niﬁcant differences in clinical and microbiological
success rates were observed.
In another multinational, randomized, double-
blind, controlled trial, linezolid was compared with
vancomycin in patients with nosocomial pneumonia
[55]. Both treatment arms also received aztre-
onam. Clinical success rate was documented in
55.6% (115/207) in the linezolid arm and 68.1%
(62/91) in the vancomycin arm. Similar micro-
biological success rates were observed in both
treatment groups (linezolid, 67.9% versus van-
comycin, 71.8%). These ﬁndings conﬁrmed the
effectiveness of linezolid for the treatment of
Gram-positive nosocomial pneumonia in adults.
Safety proﬁles
Linezolid is generally well tolerated. Based on data
collected on patients in phase 3 clinical trials,
the most common adverse effects were diarrhoea,
nausea and headache. Serious adverse events like
thrombocytopenia, abnormal liver tests and pan-
creatitis also occurred in some patients [56].
Peripheral neuropathy and optic neuropathy have
also been reported in a small number of patients
receiving linezolid [57]. As linezolid potentially
causes dose- and time-dependent reversible myelo-
suppression, weekly monitoring of blood counts
is necessary particularly with therapy of up to
a
i
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weeks duration [39,58]. Because linezolid is a
ild, reversible, nonselective monoamine oxidase
MAO) inhibitor, the potential for interaction with
drenergic or serotonergic drugs and with foods
ontaining large amount of tyramine exists. There-
ore, because of the risk of serotonin syndrome,
dministration of linezolid for patients receiving
erotonergic agents, including antidepressants such
s selective serotonin reuptake inhibitors should
e avoided. However, available data [42] indicates
hat co-administration of linezolid with adrenergic
gents resulted in increases in blood pressure but
hese were within levels associated with normal
aily activities.
uinupristin—dalfopristin
his antibiotic is a combination of quinupristin
type B streptogramin) and dalfopristin (type A
treptogramin) at a ratio of 30:70, respectively.
lthough these two streptogramins which are struc-
urally distinct cyclic peptide antibiotics have a
acteriostatic effect individually, when combined
n the appropriate ratio, they have a synergistic
actericidal effect [59]. The two components bind
o different sites on the bacterial 50S ribosome
eading to inhibition of protein synthesis [60]. Dal-
opristin blocks an early step in protein synthesis,
hereas quinupristin blocks a later step preventing
eptide extension.
Quinupristin—dalfopristin is poorly absorbed
fter oral administration and thus it is given as
n intravenous infusion. The maximum concentra-
ion (Cmax) ranges from 0.95mg/L to 24.2mg/L
ith a linear relationship between dose and Cmax.
aximum tissue concentration is usually achieved
ithin 24 h of administration with excellent pene-
ration into the liver, kidney, spleen, blood, bone
arrow, salivary glands, adrenals and the intesti-
al contents. Protein binding is approximately 11%
or quinupristin and 26% for dalfopristin. Both
uinupristin and dalfopristin are metabolized to
everal active metabolites which contribute to the
ntimicrobial activity [61]. Elimination of the main
ompounds and their active metabolites occurs
argely through hepatic clearance and fecal (biliary)
limination [62].
This combination is effective against a range
f Gram-positive organisms that are usually resis-
ant to other agents, including E. faecium, S.
ureus and S. pneumoniae [63,64]. Excellent
n vitro activity with an MIC of <1g/ml has
een demonstrated in up to 90% of strains
f multidrug-resistant Gram-positive organisms,
ncluding MSSA, MRSA, coagulase-negative staphy-
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[reatment for infections caused by drug-resistant G
ococci (CNS), penicillin-susceptible and -resistant
. pneumoniae, S. pyogenes, S. oralis and E.
aecium [65,66]. However, strains of E. faecalis
end to be resistant to quinupristin—dalfopristin.
his drug also shows activity against Mycoplasma
pp., Haemophilus inﬂuenzae, Legionella spp. and
naerobes (Clostridium spp. excluding C. difﬁcile,
eptococcus spp. and Peptostreptococcus spp.)
66]. It is approved for the treatment of infections
aused by susceptible strains of vancomycin-
esistant E. faecium (VREF) and for the treatment
f cSSSI caused by methicillin-susceptible S. aureus
r S. pyogenes in adults.
linical trials
wo large randomized, open-labelled clinical tri-
ls have been conducted in patients (n = 893) with
omplicated Gram-positive cSSSI [67]. The studies
ompared quinupristin—dalfopristin with cefazolin,
xacillin and vancomycin. The clinical success
ate was 68% for the quinupristin—dalfopristin
roup versus 71%, for the comparator regimen.
his indicates that, quinupristin—dalfopristin rep-
esents an effective alternative for the treatment
f cSSSI caused by susceptible Gram-positive
rganisms. In another large study, patients with
acteremia of unknown origin, bone and joint infec-
ion, catheter-related bacteremia, intra-abdominal
nfection, cSSSI and UTIs [68] were treated using iv
uinupristin—dalfopristin, 7.5mg/kg administered
v every 8 h. The clinical success rate was 74%
95% CI 67—80%) and the bacteriologic success rate
as 71% (95% CI 65—78%). The overall clinical
nd bacteriologic success rate was 66%. However,
uperinfection by Gram-positive organisms was doc-
mented in 22% of patients.
The efﬁcacy of quinupristin—dalfopristin in noso-
omial pneumonia was evaluated in a large phase
prospective, randomized study conducted in sev-
ral countries in which it was compared (with or
ithout aztreonam) to vancomycin [69]. A total
f 298 patients were enrolled in the study. In
he bacteriologically evaluable patients, therapy
as clinically successful (i.e., cure or improve-
ent) in 49 (56%) of the 87 patients who
eceived quinupristin—dalfopristin and 49 (58%) of
4 patients who were given vancomycin.
afety proﬁlehe most commonly reported adverse effects
ere arthralgias and/or myalgias [69,70]. Labora-
ory abnormalities were uncommon, but elevated
evels of bilirubin and transaminases have been
eported. Themost frequently reported side effects
i
a
o
b
a-positive cocci 69
ttributed to quinupristin—dalfopristin in the clin-
cal studies were muscle and joint pain, nausea,
iarrhoea, vomiting and rash. In studies in which
he drug was administered through a peripheral
ein (e.g. in the arm), many patients experienced
ocal reactions to the injection, including pain
nd inﬂammation at the catheter injection site.
uinupristin—dalfopristin has many drug interac-
ions due to its ability to inhibit the metabolism
f drugs metabolized by the cytochrome P450
62].
albavancin
his is a new semi-synthetic second genera-
ion lipoglycopeptide antibiotic designed as an
mprovement on the currently available natural gly-
opeptides (vancomycin and teicoplanin). It exerts
ts bactericidal activity by binding to the terminal
-alanyl-D-alanine moiety of the peptidoglycan pre-
ursors which results in the blockage of enzymes
nvolved in the ﬁnal stages of peptidoglycan syn-
hesis and cell wall formation [71]. Although this
s the same mechanism seen in the other gly-
opeptides, dalbavancin is much more potent than
ancomycin and teicoplanin. Hence it has been
ostulated that dalbavancin exerts its bactericidal
ffect on bacteria through more than one mecha-
ism [72]. It has been suggested that dalbavancin
ay inhibit transglycosylases, such as S. aureus
enicillin-binding protein 2 (PBP2), by direct inter-
ction with enzymes involved in the ﬁnal stages of
eptidoglycan synthesis [73].
Dalbavancin is poorly absorbed after oral
dministration hence parenteral administration is
ecommended [74]. This drug penetrates well into
variety of bodily tissues and ﬂuids with about
5% bound to plasma proteins [71]. Perhaps the
ost remarkable pharmacokinetic characteristic of
albavancin is its long terminal half-life [74]. Fol-
owing single and multiple doses, the reported
erminal half-life of dalbavancin is 149—188 h and
84—198 h, respectively. This long half-life is likely
o be due to the extensive protein-binding of
he agent which allows prolonged dosing inter-
als, that can be once weekly for some indications.
fter intravenous administration of dalbavancin,
5% of the dose is excreted unchanged in the urine
71].
While the spectrum of activity of dalbavancin
s similar to the other glycopeptides, it has the
dvantage of exhibiting superior in vitro activity
ver vancomycin or teicoplanin against suscepti-
le and multidrug-resistant pathogens, including S.
ureus, CoNS, S. pyogenes, S. pneumoniae, most
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enterococci (except VanA phenotype), Corynebac-
terium spp. and Gram-positive anaerobes [71]. It
has potent antimicrobial activity against resistant
Gram-positive pathogens including MRSA and VRE.
Clinical trials
The efﬁcacy and safety of dalbavancin versus
vancomycin were evaluated by randomized, con-
trolled, open-label phase 2 study of 75 adults with
catheter-related bloodstream infections caused by
Gram-positive pathogens [75]. Patients received
intravenous dalbavancin (1000mg stat followed by
500mg iv 1 week later) or vancomycin (1 g iv bid
for up to 14 days). Clinical response was deﬁned
as cure or improvement of infection at follow-up
visit such that no additional antibiotic treatment
was warranted. Overall success rates were 87% (95%
CI, 73.2—100.0%) for dalbavancin versus 50% (95%
CI, 31.5—68.5%) for vancomycin. Recently, Seltzer
et al. [76] conducted a randomized, controlled,
open-label trial designed to evaluate the efﬁcacy
and safety of dalbavancin in skin and soft-tissue
infections (cSSSI) that were known or suspected
to be caused by Gram-positive bacteria, including
MSSA, MRSA, Group B Streptococcus and S. pyo-
genes. A total of 62 patients were randomized to
receive a single 1100mg IV infusion of dalbavancin,
a 1000mg dose of dalbavancin followed by a 500mg
dose administered 1-week later, or a prospectively
deﬁned standard-of-care regimen determined by
the investigator before randomization. Results from
this study demonstrated that clinical success rates
were 61.5% for single-dose dalbavancin, 94.1%
for two doses of dalbavancin and 76.2% for the
standard-of-care regimen. The study showed that
two doses of dalbavancin, administered 1-week
apart, are effective for the treatment of SSTIs. A
randomized, double-blind, controlled study com-
paring dalbavancin and linezolid has also been
conducted in patients with cSSSIs [77]. Both drugs
demonstrated comparable efﬁcacy in the clini-
cally evaluable population at the test-of-cure visit
(88.9% and 91.2% clinical success rates, respec-
tively). The reported microbiological success rates
were comparable at 89.5% (dalbavancin) and 87.5%
(linezolid). These ﬁndings indicate that dalbavancin
is an effective treatment for adults with Gram-
positive cSSSIs including those caused by MRSA
and two doses of dalbavancin administered 1-week
apart were as effective as 14-day twice-daily dosing
regimen of linezolid. In addition, in the evaluation
of the efﬁcacy of dalbavancin versus either line-
zolid, cefazolin or vancomycin for the treatment
of skin and SSSIs caused by S. aureus, the clinical
and microbiological success rates of patients who
FK. Banwan et al.
eceived dalbavancin were similar to the response
ates noted for the comparator agents [71].
afety proﬁle
albavancin has been found to have a relatively
ood safety proﬁle and the reported adverse effects
nclude nausea, diarrhoea, constipation, oral can-
idiasis, pyrexia and hypotension [71]. Laboratory
bnormalities including raised liver enzymes and
ypokalemia have also been reported.
ther emerging antibiotics
n addition to the ﬁve antibiotics reviewed above,
here are also a number of other important novel
gents being investigated for use in the treatment
f infections caused by Gram-positive bacteria.
hese include telavancin which is a semi-synthetic
erivative of vancomycin and ceftobiprole which
s a -lactamase stable cephalosporin with strong
fﬁnity for the penicillin binding proteins PBP2a
nd PBP2x. Telavancin has been shown to be use-
ul in the treatment of cSSSI with cure rates of up
o 96%. In several phase 3 trials, the efﬁcacy of
eftobiprole for the treatment of cSSSI was compa-
able to that of iv vancomycin. Other agents under
nvestigation include doripenem, iclaprim (new dia-
onipyrimidine), ranbezolide (new oxazolidinone)
nd ceftaroline (new cephalosporin with anti-MRSA
nd anti-pneumococcal activity).
onclusion
aptomycin, tigecycline, linezolid, quinupristin—
alfopristin and dalbavancin are alternative antimi-
robial agents useful for the treatment of infections
ue to drug-resistant Gram-positive cocci. The
urrent body of evidence demonstrates their con-
inued clinical efﬁcacy in the management of
hese infections. However, as the search for
ewer antimicrobial agents continues, judicious
nd responsible usage of these ﬁve antibiotics is
dvocated so as to preserve their continued effec-
iveness in the management of difﬁcult-to-treat
nfections caused by Gram-positive pathogens.
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